Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli

Brief Report

Abstract

While the development of resistance to a new antibiotic is expected, the time course and degree of resistance that will develop are uncertain. Some best projections of the future extent of resistance can be highly impactful for activities, such as antimicrobial development, that require significant lead time. We focus on the surge among hospital isolates in fluoroquinolone-resistant Escherichia coli and use data on resistance and consumption to explore and quantify trends in increasing resistance and their relationship to antibiotic use from 2001 to 2007. A mixed-effects logistic regression model produced a good fit to the observed resistance rates during this period in the United States and Europe. The model contained significant effects of time, consumption, and country on developing fluoroquinolone resistance in E. coli. There was a larger projected increase in resistance for high fluoroquinolone-consuming countries projected to 2013: 45% (95% confidence interval [CI]: 38%, 53%) for high consumers vs. 33% (95% CI: 25%, 41%) for low consumers. The model was also used to obtain regional projections of resistance that can be used by local prescribers. In order to better understand and predict trends in antimicrobial resistance, it is vital to implement and expand current surveillance systems.

References

  1. 1.
    Reichert JM (2003) Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2:695–702CrossRefPubMedGoogle Scholar
  2. 2.
    Neu HC (1987) Ciprofloxacin: an overview and prospective appraisal. Am J Med 82:395–404PubMedGoogle Scholar
  3. 3.
    The European Antimicrobial Resistance Surveillance System (2007) EARSS Annual Report 2007. Available online at: http://www.rivm.nl/earss/Images/EARSS%202007_FINAL_tcm61-55933.pdf
  4. 4.
    Jones RN, Kirby JT, Rhomberg PR (2008) Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 61:203–213CrossRefPubMedGoogle Scholar
  5. 5.
    Anderson RM (1999) The pandemic of antibiotic resistance. Nat Med 5:147–149CrossRefPubMedGoogle Scholar
  6. 6.
    Lipsitch M (2001) The rise and fall of antimicrobial resistance. Trends Microbiol 9:438–444CrossRefPubMedGoogle Scholar
  7. 7.
    Bates DM (2008) Linear mixed model implementation in lme4. Department of Statistics, University of Wisconsin, Madison, WIGoogle Scholar
  8. 8.
    SAS Institute Inc. (2003) SAS OnlineDoc 9.1.2. SAS Institute Inc., Cary, NC. Available online at: http://support.sas.com/onlinedoc/912/docMainpage.jsp

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • L. K. Durham
    • 1
  • M. Ge
    • 1
  • A. J. Cuccia
    • 1
  • J. P. Quinn
    • 1
  1. 1.PfizerNew LondonUSA

Personalised recommendations